| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 20 | 2025 | 311 | 6.810 |
Why?
|
| Ischemia | 22 | 2025 | 383 | 6.110 |
Why?
|
| Endovascular Procedures | 17 | 2025 | 769 | 3.180 |
Why?
|
| Vascular Surgical Procedures | 13 | 2025 | 560 | 3.160 |
Why?
|
| Limb Salvage | 19 | 2025 | 137 | 2.510 |
Why?
|
| Lower Extremity | 9 | 2025 | 188 | 2.390 |
Why?
|
| Sirtuin 1 | 4 | 2021 | 52 | 1.870 |
Why?
|
| Blood Vessel Prosthesis Implantation | 11 | 2022 | 787 | 1.820 |
Why?
|
| Vascular System Injuries | 4 | 2021 | 59 | 1.820 |
Why?
|
| DNA, Mitochondrial | 5 | 2025 | 233 | 1.710 |
Why?
|
| Stents | 11 | 2020 | 876 | 1.500 |
Why?
|
| Wound Healing | 10 | 2025 | 495 | 1.340 |
Why?
|
| Risk Factors | 36 | 2025 | 11054 | 1.330 |
Why?
|
| Intestinal Fistula | 3 | 2020 | 28 | 1.280 |
Why?
|
| Vascular Fistula | 3 | 2020 | 31 | 1.260 |
Why?
|
| Risk Assessment | 18 | 2025 | 3682 | 1.250 |
Why?
|
| Aortic Diseases | 4 | 2019 | 203 | 1.180 |
Why?
|
| Carotid Stenosis | 3 | 2019 | 134 | 1.130 |
Why?
|
| Time Factors | 26 | 2025 | 6578 | 1.130 |
Why?
|
| Cardiovascular Agents | 2 | 2022 | 91 | 1.100 |
Why?
|
| Prosthesis-Related Infections | 4 | 2022 | 185 | 1.090 |
Why?
|
| Endodeoxyribonucleases | 2 | 2025 | 50 | 1.080 |
Why?
|
| Diabetic Foot | 6 | 2025 | 164 | 1.010 |
Why?
|
| Arteries | 2 | 2017 | 222 | 0.990 |
Why?
|
| Treatment Outcome | 35 | 2025 | 12987 | 0.990 |
Why?
|
| Chronic Disease | 10 | 2025 | 1252 | 0.990 |
Why?
|
| Mitochondria, Liver | 1 | 2025 | 34 | 0.930 |
Why?
|
| Aged | 40 | 2025 | 21664 | 0.910 |
Why?
|
| Retrospective Studies | 33 | 2025 | 17413 | 0.850 |
Why?
|
| Subclavian Artery | 2 | 2016 | 73 | 0.840 |
Why?
|
| Cardiovascular System | 1 | 2024 | 111 | 0.830 |
Why?
|
| Sex Distribution | 2 | 2021 | 330 | 0.830 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2017 | 763 | 0.820 |
Why?
|
| Mitochondria | 6 | 2025 | 737 | 0.810 |
Why?
|
| Humans | 77 | 2025 | 133454 | 0.780 |
Why?
|
| Inflammasomes | 2 | 2023 | 164 | 0.750 |
Why?
|
| Aortic Aneurysm, Abdominal | 3 | 2019 | 444 | 0.740 |
Why?
|
| Male | 48 | 2025 | 65712 | 0.740 |
Why?
|
| Adenylate Kinase | 1 | 2021 | 13 | 0.740 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2021 | 7 | 0.730 |
Why?
|
| Middle Aged | 35 | 2025 | 29299 | 0.730 |
Why?
|
| Drug-Eluting Stents | 1 | 2022 | 70 | 0.720 |
Why?
|
| Mitochondria, Muscle | 1 | 2021 | 38 | 0.720 |
Why?
|
| Voltage-Dependent Anion Channels | 2 | 2023 | 32 | 0.710 |
Why?
|
| Patient Selection | 5 | 2021 | 732 | 0.700 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 136 | 0.700 |
Why?
|
| Postoperative Complications | 6 | 2025 | 3208 | 0.690 |
Why?
|
| Chi-Square Distribution | 9 | 2017 | 604 | 0.660 |
Why?
|
| Angioplasty, Balloon | 4 | 2016 | 162 | 0.660 |
Why?
|
| Mitochondrial Membranes | 1 | 2019 | 31 | 0.650 |
Why?
|
| Vascular Diseases | 1 | 2021 | 158 | 0.650 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 187 | 0.650 |
Why?
|
| Aorta, Abdominal | 3 | 2019 | 125 | 0.630 |
Why?
|
| Protein Multimerization | 1 | 2019 | 143 | 0.620 |
Why?
|
| Aorta, Thoracic | 3 | 2018 | 539 | 0.610 |
Why?
|
| Endarterectomy, Carotid | 1 | 2019 | 94 | 0.590 |
Why?
|
| Female | 44 | 2025 | 71471 | 0.580 |
Why?
|
| Renal Dialysis | 1 | 2024 | 875 | 0.560 |
Why?
|
| Adenosine Triphosphate | 2 | 2023 | 294 | 0.550 |
Why?
|
| Forecasting | 1 | 2019 | 375 | 0.550 |
Why?
|
| Aorta | 3 | 2021 | 557 | 0.540 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 34 | 0.540 |
Why?
|
| Registries | 4 | 2020 | 1558 | 0.530 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2019 | 212 | 0.530 |
Why?
|
| Kidney Failure, Chronic | 1 | 2024 | 911 | 0.530 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1153 | 0.520 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2024 | 1135 | 0.520 |
Why?
|
| Femoral Vein | 2 | 2017 | 49 | 0.510 |
Why?
|
| Surgical Flaps | 1 | 2018 | 212 | 0.500 |
Why?
|
| Axillary Artery | 1 | 2016 | 28 | 0.500 |
Why?
|
| Depression | 1 | 2025 | 1348 | 0.500 |
Why?
|
| Cause of Death | 1 | 2018 | 502 | 0.490 |
Why?
|
| Diabetes Complications | 1 | 2017 | 207 | 0.480 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2017 | 177 | 0.480 |
Why?
|
| Blood Vessel Prosthesis | 4 | 2022 | 539 | 0.480 |
Why?
|
| Health Status Disparities | 2 | 2024 | 245 | 0.470 |
Why?
|
| Signal Transduction | 5 | 2023 | 4882 | 0.470 |
Why?
|
| Aneurysm, Infected | 2 | 2012 | 24 | 0.460 |
Why?
|
| Aneurysm, False | 2 | 2012 | 94 | 0.420 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 360 | 0.400 |
Why?
|
| Prevalence | 3 | 2025 | 2654 | 0.400 |
Why?
|
| Oxygen Consumption | 2 | 2025 | 316 | 0.400 |
Why?
|
| Vascular Patency | 4 | 2020 | 196 | 0.390 |
Why?
|
| Cardiovascular Infections | 1 | 2012 | 7 | 0.390 |
Why?
|
| Glucose | 1 | 2017 | 923 | 0.390 |
Why?
|
| Thrombophlebitis | 1 | 2012 | 21 | 0.380 |
Why?
|
| United States | 13 | 2024 | 11645 | 0.380 |
Why?
|
| Popliteal Vein | 1 | 2011 | 9 | 0.380 |
Why?
|
| Venous Thrombosis | 3 | 2023 | 169 | 0.370 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 2077 | 0.370 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 932 | 0.370 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2010 | 86 | 0.330 |
Why?
|
| Incidence | 5 | 2025 | 3385 | 0.320 |
Why?
|
| Proportional Hazards Models | 5 | 2024 | 1478 | 0.320 |
Why?
|
| Myocardial Infarction | 3 | 2023 | 1096 | 0.310 |
Why?
|
| Mice | 10 | 2025 | 18818 | 0.310 |
Why?
|
| Exercise Therapy | 2 | 2023 | 180 | 0.310 |
Why?
|
| Atherosclerosis | 2 | 2016 | 997 | 0.310 |
Why?
|
| Thrombectomy | 3 | 2024 | 104 | 0.310 |
Why?
|
| Machine Learning | 2 | 2023 | 325 | 0.310 |
Why?
|
| Critical Illness | 5 | 2019 | 621 | 0.310 |
Why?
|
| Quality of Life | 3 | 2024 | 2125 | 0.310 |
Why?
|
| Cyclic AMP | 2 | 2021 | 262 | 0.300 |
Why?
|
| Sex Factors | 3 | 2024 | 1381 | 0.300 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 3065 | 0.300 |
Why?
|
| Texas | 7 | 2016 | 3681 | 0.300 |
Why?
|
| Cross Infection | 1 | 2011 | 332 | 0.300 |
Why?
|
| Survival Rate | 5 | 2020 | 2199 | 0.290 |
Why?
|
| Stroke | 3 | 2016 | 1068 | 0.290 |
Why?
|
| Hospital Mortality | 4 | 2019 | 1072 | 0.280 |
Why?
|
| Protein Domains | 2 | 2019 | 251 | 0.280 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1487 | 0.270 |
Why?
|
| Recovery of Function | 3 | 2025 | 473 | 0.270 |
Why?
|
| Acute Disease | 4 | 2024 | 1185 | 0.270 |
Why?
|
| Reoperation | 4 | 2022 | 866 | 0.260 |
Why?
|
| Liver | 4 | 2025 | 1850 | 0.260 |
Why?
|
| Logistic Models | 6 | 2017 | 1905 | 0.250 |
Why?
|
| Vascular Grafting | 2 | 2018 | 48 | 0.250 |
Why?
|
| Nucleotidyltransferases | 2 | 2023 | 46 | 0.250 |
Why?
|
| Aged, 80 and over | 12 | 2024 | 7183 | 0.250 |
Why?
|
| Mice, Knockout | 4 | 2025 | 3958 | 0.250 |
Why?
|
| Device Removal | 2 | 2021 | 221 | 0.250 |
Why?
|
| Comorbidity | 3 | 2017 | 1606 | 0.240 |
Why?
|
| Animals | 11 | 2025 | 36277 | 0.240 |
Why?
|
| Leg | 1 | 2006 | 156 | 0.240 |
Why?
|
| Cell Respiration | 1 | 2025 | 24 | 0.240 |
Why?
|
| Fatty Liver | 2 | 2025 | 210 | 0.230 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2025 | 51 | 0.230 |
Why?
|
| Embolism | 1 | 2024 | 48 | 0.220 |
Why?
|
| Odds Ratio | 4 | 2017 | 1337 | 0.210 |
Why?
|
| Myofibrils | 1 | 2023 | 27 | 0.210 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2025 | 147 | 0.210 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 317 | 0.210 |
Why?
|
| Intermittent Claudication | 1 | 2023 | 60 | 0.210 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 3738 | 0.210 |
Why?
|
| Delphi Technique | 1 | 2024 | 242 | 0.210 |
Why?
|
| Early Ambulation | 1 | 2022 | 9 | 0.200 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2023 | 127 | 0.200 |
Why?
|
| Predictive Value of Tests | 3 | 2025 | 2302 | 0.200 |
Why?
|
| Angioplasty | 2 | 2014 | 80 | 0.190 |
Why?
|
| Thrombosis | 2 | 2024 | 536 | 0.190 |
Why?
|
| Leg Ulcer | 1 | 2021 | 12 | 0.190 |
Why?
|
| Rolipram | 1 | 2021 | 3 | 0.190 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 969 | 0.180 |
Why?
|
| Organelle Biogenesis | 1 | 2021 | 19 | 0.180 |
Why?
|
| Renal Artery Obstruction | 2 | 2012 | 42 | 0.180 |
Why?
|
| Patient Advocacy | 1 | 2021 | 62 | 0.180 |
Why?
|
| Paclitaxel | 1 | 2022 | 142 | 0.180 |
Why?
|
| Prognosis | 2 | 2023 | 5058 | 0.180 |
Why?
|
| Oxygen | 2 | 2022 | 576 | 0.180 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2021 | 107 | 0.170 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 57 | 0.170 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2020 | 22 | 0.170 |
Why?
|
| Recurrence | 2 | 2016 | 1467 | 0.170 |
Why?
|
| Retreatment | 2 | 2019 | 92 | 0.170 |
Why?
|
| History, 21st Century | 1 | 2021 | 278 | 0.170 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2020 | 88 | 0.170 |
Why?
|
| Integrins | 1 | 2020 | 103 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 203 | 0.170 |
Why?
|
| Coinfection | 1 | 2022 | 182 | 0.170 |
Why?
|
| Immunity, Innate | 1 | 2023 | 407 | 0.170 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 2 | 2017 | 43 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5487 | 0.160 |
Why?
|
| Tissue Scaffolds | 1 | 2020 | 84 | 0.160 |
Why?
|
| Frail Elderly | 1 | 2020 | 107 | 0.160 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 229 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 279 | 0.160 |
Why?
|
| HEK293 Cells | 3 | 2017 | 808 | 0.160 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 190 | 0.160 |
Why?
|
| Colitis | 1 | 2021 | 173 | 0.160 |
Why?
|
| Osteogenesis | 1 | 2020 | 167 | 0.160 |
Why?
|
| Iliac Artery | 1 | 2019 | 81 | 0.160 |
Why?
|
| Wearable Electronic Devices | 1 | 2020 | 107 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 133 | 0.150 |
Why?
|
| Pain | 1 | 2022 | 478 | 0.150 |
Why?
|
| Interferons | 1 | 2019 | 145 | 0.150 |
Why?
|
| Disease Progression | 1 | 2025 | 2235 | 0.150 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 387 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 480 | 0.150 |
Why?
|
| Frailty | 1 | 2020 | 131 | 0.140 |
Why?
|
| Adult | 12 | 2021 | 31880 | 0.140 |
Why?
|
| Wound Infection | 1 | 2018 | 54 | 0.140 |
Why?
|
| Phosphorylation | 3 | 2020 | 1699 | 0.140 |
Why?
|
| Myocytes, Cardiac | 1 | 2023 | 672 | 0.140 |
Why?
|
| Membrane Proteins | 2 | 2023 | 1605 | 0.140 |
Why?
|
| Inflammation | 2 | 2023 | 1595 | 0.140 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 2656 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2022 | 5176 | 0.140 |
Why?
|
| Patient Participation | 1 | 2020 | 234 | 0.140 |
Why?
|
| Thoracic Injuries | 1 | 2018 | 93 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 236 | 0.140 |
Why?
|
| Surgical Mesh | 1 | 2018 | 68 | 0.140 |
Why?
|
| Ankle Joint | 1 | 2017 | 35 | 0.140 |
Why?
|
| Wounds, Penetrating | 1 | 2018 | 141 | 0.140 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 104 | 0.140 |
Why?
|
| Length of Stay | 2 | 2020 | 1374 | 0.140 |
Why?
|
| Deoxyglucose | 1 | 2017 | 41 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 349 | 0.140 |
Why?
|
| Abdominal Injuries | 1 | 2018 | 117 | 0.130 |
Why?
|
| Laparotomy | 1 | 2018 | 142 | 0.130 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2017 | 70 | 0.130 |
Why?
|
| Glasgow Coma Scale | 1 | 2017 | 200 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 324 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2023 | 681 | 0.130 |
Why?
|
| Injury Severity Score | 1 | 2017 | 232 | 0.130 |
Why?
|
| Video Games | 1 | 2017 | 92 | 0.130 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2017 | 93 | 0.130 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2017 | 326 | 0.130 |
Why?
|
| Adipogenesis | 1 | 2017 | 79 | 0.130 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2016 | 55 | 0.130 |
Why?
|
| Glucose Intolerance | 1 | 2017 | 84 | 0.130 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2018 | 219 | 0.130 |
Why?
|
| Plasmids | 1 | 2017 | 525 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 894 | 0.120 |
Why?
|
| Transcription Factors | 2 | 2017 | 2702 | 0.120 |
Why?
|
| Binding Sites | 2 | 2017 | 1368 | 0.120 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 269 | 0.120 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2015 | 37 | 0.120 |
Why?
|
| HeLa Cells | 1 | 2017 | 827 | 0.120 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 231 | 0.120 |
Why?
|
| RNA Interference | 1 | 2017 | 540 | 0.120 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 209 | 0.120 |
Why?
|
| Embolization, Therapeutic | 1 | 2017 | 223 | 0.120 |
Why?
|
| Caregivers | 1 | 2020 | 585 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 4 | 2017 | 4789 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 712 | 0.110 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 711 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 3986 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 90 | 0.110 |
Why?
|
| Kidney | 2 | 2012 | 1405 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2019 | 861 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2018 | 1596 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2021 | 1146 | 0.110 |
Why?
|
| Muscle, Skeletal | 2 | 2017 | 1051 | 0.110 |
Why?
|
| Metatarsal Bones | 2 | 2024 | 8 | 0.110 |
Why?
|
| Life Style | 1 | 2016 | 454 | 0.110 |
Why?
|
| Vesicular Transport Proteins | 1 | 2014 | 121 | 0.110 |
Why?
|
| Triplets | 1 | 2013 | 12 | 0.100 |
Why?
|
| Radiology, Interventional | 1 | 2013 | 34 | 0.100 |
Why?
|
| Rats | 1 | 2019 | 3874 | 0.100 |
Why?
|
| Weight Loss | 1 | 2017 | 515 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 478 | 0.100 |
Why?
|
| Radiation Dosage | 1 | 2013 | 144 | 0.100 |
Why?
|
| Radiography, Interventional | 1 | 2013 | 88 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2017 | 1243 | 0.100 |
Why?
|
| Aneurysm | 1 | 2013 | 89 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2016 | 1195 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 145 | 0.100 |
Why?
|
| Hypertension, Renovascular | 1 | 2011 | 29 | 0.090 |
Why?
|
| Cell Cycle | 1 | 2014 | 626 | 0.090 |
Why?
|
| Smoking Cessation | 1 | 2013 | 209 | 0.090 |
Why?
|
| Cell Line | 1 | 2017 | 2834 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 2159 | 0.090 |
Why?
|
| Carotid Artery Diseases | 1 | 2013 | 148 | 0.090 |
Why?
|
| Tuberous Sclerosis | 1 | 2013 | 124 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 1756 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2011 | 77 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2014 | 403 | 0.090 |
Why?
|
| Blood Pressure | 3 | 2011 | 1408 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2013 | 2190 | 0.090 |
Why?
|
| Smoking | 1 | 2016 | 1139 | 0.090 |
Why?
|
| Georgia | 1 | 2010 | 38 | 0.090 |
Why?
|
| Endoleak | 1 | 2010 | 47 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 1307 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2013 | 394 | 0.090 |
Why?
|
| Age Factors | 1 | 2017 | 2978 | 0.090 |
Why?
|
| Leukocytosis | 1 | 2010 | 48 | 0.080 |
Why?
|
| Ulcer | 1 | 2010 | 50 | 0.080 |
Why?
|
| Energy Metabolism | 3 | 2022 | 809 | 0.080 |
Why?
|
| Iliac Vein | 1 | 2010 | 30 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2014 | 572 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2010 | 259 | 0.080 |
Why?
|
| Bicycling | 1 | 2010 | 36 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 790 | 0.080 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2014 | 290 | 0.080 |
Why?
|
| Hematoma | 1 | 2010 | 94 | 0.080 |
Why?
|
| Elective Surgical Procedures | 1 | 2010 | 167 | 0.080 |
Why?
|
| Aortic Rupture | 1 | 2010 | 120 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 175 | 0.080 |
Why?
|
| Anesthesia | 1 | 2011 | 213 | 0.080 |
Why?
|
| Infant | 4 | 2018 | 13118 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 249 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4745 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2024 | 6649 | 0.080 |
Why?
|
| Child, Preschool | 4 | 2018 | 14758 | 0.070 |
Why?
|
| Graft Survival | 1 | 2010 | 557 | 0.070 |
Why?
|
| Hypertension | 3 | 2011 | 1389 | 0.070 |
Why?
|
| Adolescent | 5 | 2018 | 20497 | 0.070 |
Why?
|
| Child | 5 | 2023 | 25700 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1329 | 0.060 |
Why?
|
| BRCA1 Protein | 1 | 2006 | 82 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2022 | 282 | 0.060 |
Why?
|
| Femoral Artery | 1 | 2006 | 191 | 0.060 |
Why?
|
| Fasciotomy | 1 | 2024 | 26 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2009 | 504 | 0.060 |
Why?
|
| Checkpoint Kinase 2 | 3 | 2009 | 38 | 0.060 |
Why?
|
| Diffusion | 1 | 2023 | 58 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2006 | 431 | 0.050 |
Why?
|
| Young Adult | 5 | 2018 | 9880 | 0.050 |
Why?
|
| Europe | 1 | 2024 | 384 | 0.050 |
Why?
|
| Renal Veins | 1 | 2023 | 34 | 0.050 |
Why?
|
| Mutation | 1 | 2017 | 6274 | 0.050 |
Why?
|
| Suction | 1 | 2023 | 58 | 0.050 |
Why?
|
| Myoglobin | 1 | 2022 | 108 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2009 | 1611 | 0.050 |
Why?
|
| Rivaroxaban | 1 | 2022 | 55 | 0.050 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2010 | 677 | 0.050 |
Why?
|
| Water | 1 | 2023 | 198 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2025 | 276 | 0.050 |
Why?
|
| DNA Repair | 1 | 2006 | 628 | 0.050 |
Why?
|
| Biomarkers | 3 | 2021 | 3410 | 0.050 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 1 | 2021 | 24 | 0.050 |
Why?
|
| Dextran Sulfate | 1 | 2021 | 51 | 0.050 |
Why?
|
| Extracellular Traps | 1 | 2021 | 9 | 0.050 |
Why?
|
| Clinical Competence | 3 | 2014 | 1058 | 0.050 |
Why?
|
| Aspirin | 1 | 2022 | 232 | 0.040 |
Why?
|
| Organ Size | 2 | 2012 | 467 | 0.040 |
Why?
|
| Benchmarking | 1 | 2021 | 149 | 0.040 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 89 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2020 | 172 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2021 | 243 | 0.040 |
Why?
|
| Creatinine | 2 | 2012 | 423 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 1198 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2022 | 700 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 249 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2020 | 164 | 0.040 |
Why?
|
| Health Services Research | 1 | 2020 | 191 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 1405 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2020 | 230 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 505 | 0.040 |
Why?
|
| DNA Damage | 2 | 2014 | 542 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 1911 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 2 | 2012 | 536 | 0.040 |
Why?
|
| Biofeedback, Psychology | 1 | 2017 | 39 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2017 | 85 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2017 | 151 | 0.030 |
Why?
|
| Electromyography | 1 | 2017 | 176 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2017 | 226 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2021 | 757 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 462 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 263 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2017 | 197 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2020 | 636 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 291 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 504 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2017 | 466 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 541 | 0.030 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2015 | 23 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2020 | 1046 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2013 | 3474 | 0.030 |
Why?
|
| F-Box Proteins | 1 | 2015 | 37 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 137 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2017 | 315 | 0.030 |
Why?
|
| Thymocytes | 1 | 2014 | 9 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 817 | 0.030 |
Why?
|
| Adipose Tissue, Brown | 1 | 2015 | 78 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2018 | 411 | 0.030 |
Why?
|
| Carbazoles | 1 | 2014 | 35 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2015 | 147 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2014 | 132 | 0.030 |
Why?
|
| Acetylation | 1 | 2014 | 182 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1192 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1488 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 3725 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2015 | 873 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2013 | 98 | 0.030 |
Why?
|
| Histones | 1 | 2017 | 568 | 0.030 |
Why?
|
| Saphenous Vein | 1 | 2013 | 60 | 0.020 |
Why?
|
| Operating Rooms | 1 | 2013 | 75 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2015 | 369 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2020 | 2024 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 384 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2013 | 372 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2013 | 162 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2014 | 687 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 2011 | 65 | 0.020 |
Why?
|
| Insulin | 1 | 2017 | 1246 | 0.020 |
Why?
|
| Homeostasis | 1 | 2015 | 750 | 0.020 |
Why?
|
| Renal Replacement Therapy | 1 | 2012 | 151 | 0.020 |
Why?
|
| Emergencies | 1 | 2011 | 184 | 0.020 |
Why?
|
| Workload | 1 | 2011 | 151 | 0.020 |
Why?
|
| Phlebography | 1 | 2010 | 45 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1832 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2009 | 2935 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 241 | 0.020 |
Why?
|
| Pedigree | 1 | 2013 | 1693 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 409 | 0.020 |
Why?
|
| Patient Safety | 1 | 2013 | 429 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2010 | 209 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 2010 | 204 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 831 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 317 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 4525 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 3169 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 3970 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 3818 | 0.010 |
Why?
|
| Heart Failure | 1 | 2011 | 2393 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 2759 | 0.010 |
Why?
|